AARDEX Group

Harnessing Smart Pill Bottles to Improve Patient Adherence in Clinical Research

smart pill bottles

“Nothing stops a drug from working like not taking it, making patient adherence one of the most important factors to consider when designing a clinical trial.” 
– Bernard Vrijens, Scientific Lead, AARDEX® Group

Poor patient adherence is a problem that has gone “unsolved” for decades. But combining smart pill bottle technology with individualized feedback can drive the adherence that proves the investigational product efficacy and underwrites approvals.

In this case study, we set out the crucial role of medicine-taking behavior in clinical research and explain how using AARDEX® Group’s Smart Pill Bottle, MEMS® Caps, in a study of Gilead’s Truvada helped inform the FDA’s recommended approach to tackling poor patient adherence in clinical trials, as set out in its Enrichment Strategies for Clinical Trials to Support Determination of Effectiveness of Human Drugs and Biological Products.

Share This Post

You may also like...

Adherence in clinicat trials
Breaking News

The Importance of Dose Optimisation in Oncology Clinical Trials

Let us first recognise the enormity of the challenges we are facing, on a global scale, when it comes to cancer. It is estimated that there were 18.1 million new cases of cancer worldwide in 2020, with around 10 million

Press Release
Breaking News

AARDEX Group and Compliance Meds Technologies sign collaboration agreement

AARDEX Group, the global leader in medication adherence solutions, has today announced a collaboration agreement with Compliance Meds Technologies (CMT), a mobile-health technology solutions provider. In this cooperation, the partners will combine the AARDEX MEMS® Adherence Software with CMT’s CleverCap®